Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychological dimension of resource use in smallholder farming: Insights from credit access, landholding, and technology adoption in India.

Acta psychologica·2026
Same author

Radiation Synovectomy: An Enticing Treatment Option for Inflammatory Joint Pain.

Pain research & management·2025
Same author

Interpretable Automated Arrhythmia Detection: An Assistive Framework for Clinicians.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025
Same author

Sustainable practices in business operations - Merely a moral obligation of modern companies or a strategic asset for enhancing shareholders value.

Journal of environmental management·2025
Same author

Funding Innovation and Risk: A Grey-Based Startup Investment Decision.

Evaluation review·2024
Same author

Re-188 lipiodol in hepatocellular carcinoma with portal vein thrombosis: a pilot study using novel chelating agent N-DEDC and its comparison with (A)HDD.

Nuclear medicine communications·2024
Same journal

[<sup>68</sup>Ga]Ga-DOTA-TOC Synthesis by a Cassette Developer System with [<sup>68</sup>Ga]GaCl<sub>3</sub> from Cyclotron using Liquid Target: An Italian Experience.

Current radiopharmaceuticals·2025
Same journal

Evaluating the Effectiveness of Geant4 Software in Measuring the Damage Caused by Ti48 Ion Radiation on Nerve Cells, in Comparison to the Biophysical Model and Empirical Data.

Current radiopharmaceuticals·2025
Same journal

Synergistic Potential of GLP-1 Receptor Agonists and Radiotherapy in Breast Cancer Treatment: A New Therapeutic Avenue (TROD-GROG 006).

Current radiopharmaceuticals·2025
Same journal

Real-world Data on Intermediate-risk Differentiated Thyroid Cancer Biochemical Response to 3700 or 5550 MBq of [<sup>131</sup>I]Sodium Iodide.

Current radiopharmaceuticals·2025
Same journal

RNA Binding Proteins are Pivotal Regulators of Cancer Radioresistance and Potential Targets for Preventing Tumor Recurrence.

Current radiopharmaceuticals·2025
Same journal

Nuclear Nanomedicines: Utilization of Radiolabelling Strategies, Drug Formulation, Delivery, and Regulatory Aspects for Disease Management.

Current radiopharmaceuticals·2025
See all related articles

Related Experiment Video

Updated: May 7, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Targeted radionuclide therapy--an overview.

Ashutosh Dash1, F F Russ Knapp, M R A Pillai

  • 1Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai 400 085, India. pillai.m.r.a@gmail.com.

Current Radiopharmaceuticals
|September 25, 2013
PubMed
Summary
This summary is machine-generated.

Radionuclide therapy (RNT) delivers targeted radiation to disease sites at the cellular level. While effective for some cancers, RNT shows limited success in solid tumors, with future developments focusing on novel targeting agents.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Related Experiment Videos

Last Updated: May 7, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Area of Science:

  • Nuclear Medicine
  • Oncology

Background:

  • Radionuclide therapy (RNT) is a growing field in nuclear medicine, targeting diseases at the cellular level.
  • It utilizes radiolabeled agents for site-specific accumulation and targeted radiation delivery.
  • Advancements in understanding cellular biochemistry drive the development of sophisticated molecular carriers.

Purpose of the Study:

  • To review the applications of radionuclide therapy in treating various diseases.
  • To provide an overview of RNT's role in conditions like polycythaemia, thyroid cancer, bone metastases, and more.
  • To discuss recent progress, challenges, and future perspectives in RNT.

Main Methods:

  • Review of current literature on radionuclide therapy applications.
  • Discussion of factors influencing radionuclide selection (availability, emissions, LET, half-life).
  • Analysis of treatment regimen design and emerging targeting agents.

Main Results:

  • RNT has shown significant progress in treating hematological tumors.
  • Applications include polycythaemia, thyroid malignancies, metastatic bone pain, and radiation synovectomy.
  • Development for treating solid tumors remains limited.

Conclusions:

  • Novel tumor-specific targeting agents and target structures are crucial for advancing RNT in solid tumors.
  • Continued research is needed to overcome current limitations.
  • RNT holds promise for future cancer and disease treatment.